Watch out Al­ler­gan: Re­vance’s wrin­kle-re­duc­er beats Botox in PhI­II tri­als

Re­vance Ther­a­peu­tics has re­leased late-stage da­ta for a wrin­kle-re­duc­ing drug that ri­vals Botox. If it reach­es the mar­ket, the Bay Area biotech plans to go head-to-head with the gi­ant in this field: Al­ler­gan.

Re­vance $RVNC re­port­ed on two Phase III clin­i­cal tri­als of its drug, an in­jectable bot­u­linum tox­in coined RT002. The drug was test­ed against frown lines — those wrin­kles that show up be­tween your eye­brows. RT002 last­ed for six months, while Botox gen­er­al­ly on­ly lasts for three to four months. The study met its pri­ma­ry and sec­ondary end­points in the two Phase III tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER